Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.92 USD
+1.43 (1.27%)
Updated Aug 8, 2024 04:01 PM ET
After-Market: $113.99 +0.07 (0.06%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum C VGM
Brokerage Reports
Merck & Co., Inc. [MRK]
Reports for Purchase
Showing records 341 - 360 ( 399 total )
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Technicals Prescribe Long Positions in Health Care Stocks
Provider: Drexel Hamilton, LLC
Analyst: SINE B
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Zacks Earnings Trends: Will Earnings Growth Bottom in Q2? Companies mentioned- FDX, ORCL, PFE, ABT, MRK, DRI, WAG, AAPL
Provider: ZACKS INVESTMENT RESEARCH
Analyst: MIAN S
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Zacks Earning Trends: Q2 Earnings Expectations Remain Low- Companies mentioned: FDX,ORCL,DRI,GS,JPM,PFE,MRK
Provider: ZACKS INVESTMENT RESEARCH
Analyst: MIAN S
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Fourth Quarter Revenue Impacted by a Full Quarter of Generic Competition for Singulair
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Third Quarter Reflected the Singulair Patent Expiration
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S